



FOR IMMEDIATE RELEASE

Immgenuity Inc., Announces the Appointment of Dr. Satish Chandran to its Scientific Advisory Board.

Dover, Delaware, September 09, 2022 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Dr. Satish Chandran has joined its Scientific Advisory Board.

Dr. Satish Chandran is a highly respected pharmaceutical industry executive with extensive experience in drug development, clinical research, and commercialization. Dr. Chandran has decades of experience in the development and manufacturing of DNA vaccines in leadership positions with Wyeth where he was the Head of DNA vaccines and at Pfizer Biotherapeutics as Chief Technology Officer.

“Having Dr. Chandran as a key member of our scientific advisory board will give us invaluable expertise in preparing our lead drug candidate IMTV014 for clinical trials. We are grateful for his participation in helping us move IMTV014 forward”, said Dr. Sateesh Apte, Immgenuity's CEO.

“I am extremely optimistic to join Immgenuity's Scientific Advisory Board and contribute to the development of Immgenuity’s therapeutic vaccine that has the potential to make a significant impact on patients' lives,” said Dr. Chandran. “Immgenuity's innovative approach to achieving a remission in HIV and its focus on addressing this unmet medical need aligns with my own values and passion for improving patient outcomes.”

Immgenuity's Scientific Advisory Board is composed of world-renowned experts in the fields of Virology, immunology, and Infectious Diseases, particularly HIV. The Board provides guidance and strategic advice to Immgenuity's leadership team on the research and development of its innovative therapies.

About Immgenuity, Inc.

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

About IMTV014

Immgenuity’s immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.